Recent Updates
Recently added Catalysts

ABVC BioPharma, Inc.

ABVCFDA catalysts, PDUFA dates & pipeline intelligence
$0.88
▼ -0.03 · -3.34%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ABVC financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.7152W HIGH $2.94
Volume
57.51 K
Value Traded
51.03 K
Short % Float
2.73%
Days to Cover
19.9
-8.68%Week
-5.38%1 Month
-1.11%3 Month
-20.72%6 Month
-97.89%5 Year
-100%All Time

Cash Data

Unlock ABVC cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
23.74 M
EPS (TTM)
-0.15
P/E Ratio
-
Ent. Value
23.70 M
Total Shares
26.98 M
Float Shares
22.10 M
Insiders
18.09%
Institutions
4.88%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every ABVC catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ABVC Catalyst Timeline

Dated clinical, regulatory and corporate events for ABVC BioPharma, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for ABVC BioPharma, Inc.

161Total events
2Upcoming
40Tier-1 (high impact)
2006 to 2026Coverage

Upcoming catalysts 2

TBD
T3Legal / Settlement
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Vitargus

Event history 50

▼Equity OfferingCorporate
Closing of $3.39 million private placement of OID senior convertible notes
●Quarterly UpdateCorporate
Filed Annual Report on Form 10-K for fiscal year ended December 31, 2025
●Quarterly UpdateCorporate
Q3 2025 financial results reported
●Quarterly UpdateCorporate
Reported Q2 2025 financial results with diluted loss per share of $(0.13)
◆Quarterly UpdateCorporate
Deadline to regain Nasdaq bid price compliance
▲Partnership / LicenseCorporate
Received $350,000 in licensing revenue from AiBtl BioPharma, OncoX BioPharma, and ForSeeCon Eye Corporation in July 2025
●AcquisitionCorporate
Completed acquisition of farmland in Taiwan valued at ~$3.3 million for R&D and GMP expansion
▲Quarterly UpdateCorporate
Regained Nasdaq minimum bid price compliance
●Quarterly UpdateCorporate
First Quarter 2025 Financial Results
▲Quarterly UpdateCorporate
Announced 2024 financial results with revenue up 234%, expenses down 21%, EPS improvement of 77%
Unlock the full ABVC catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ABVC actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2023-12-31ABV-1505 Phase 2b interim results Phase 2b
Unlock all ABVC historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 68%
Micro Cap
(rank 492 of 723)
Percentile Rank
Showing 6 of 6 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
BLEX 404 Small MoleculesNCT02944955Myelodysplastic Syndrome (MDS)Phase 2 NOT YET_RECRUITING 52Dec 31, 2028
BLEX 404 Small MoleculesNCT02802423Triple Negative Breast CancerPhase 1/2 NOT YET_RECRUITING 44Aug 28, 2028
BLEX 404 Small MoleculesNCT05764928Nonsquamous Nonsmall Cell Neoplasm of LungPhase 1/2 NOT YET_RECRUITING 32Dec 31, 2028
BLEX 404 Small MoleculesNCT03301805Pancreatic CancerPhase 2 NOT YET_RECRUITING 40Jun 30, 2027
PDC-1421 Small MoleculesNCT01774045Major Depressive DisorderPhase 2 COMPLETED 114Jul 1, 2013
PDC-1421 Small MoleculesCompletedNCT02699086Attention-Deficit Hyperactivity Disorder (ADHD)Phase 2 COMPLETED 105Jul 15, 2020
Unlock the ABVC pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ABVC program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every ABVC trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ABVC insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full ABVC insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in ABVC for Q3 2026.
Unlock every fund holding ABVC
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ABVC
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see ABVC ownership
Insider and institutional ownership, quarter by quarter.

ABVC Short Interest

Shares sold short, counted twice a month.

2.73%
Short % of Float
of tradable shares sold short
602.9K
Shares Sold Short
+2.2% vs prior count
19.9 Very high
Days to Cover
trading days of normal volume to buy every short share back
30.3K
Avg Daily Volume
the average used for days to cover
Unlock ABVC short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock ABVC option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ABVC option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ABVC options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ABVC ranks across every disease it competes in

Competitive Position is a premium feature
See how ABVC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ABVC News

ABVC
Nov 2, 2026
ABVCGeneral
▼ -6.6%on this news

ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million

ABVC BioPharma announced the closing of a private placement of convertible promissory notes, raising approximately $3.39 million. The funds will be used for working capital, subsidiary support, and a settlement payment. The company aims to advance its pharmaceutical portfolio through strategic initiatives and partnerships.

Read more →
ABVC
Mar 3, 2026
ABVCGeneral

ABVC BioPharma Reports 2025 Form 10-K

ABVC BioPharma reported a significant increase in total assets, rising 179% to $21.06 million for the fiscal year ended December 31, 2025, according to their Form 10-K filing. The company emphasizes its strategic acquisition of land assets in Asia as a cornerstone of its asset-backed licensing model. This approach is designed to separate development risks from long-term value, enhancing the financial efficiency of the company. ABVC BioPharma aims to evolve towards a hybrid asset model that combines real assets with its existing intellectual property-driven framework.

Read more →
ABVC
Nov 3, 2025
ABVCGeneral
▲ +5.7%on this news

ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025

ABVC BioPharma reported impressive financial results for Q3 2025, highlighting a 230% increase in year-over-year licensing revenue and a 181% expansion in assets. The company's focus on an asset-light business model has allowed it to pursue growth through partnerships and collaborations, particularly in the central nervous system, ophthalmology, and oncology sectors. CEO Dr. Uttam Patil expressed confidence in the company’s strategic priorities aimed at long-term shareholder value. ABVC's active pipeline includes six drugs and one medical device currently under development.

Read more →
ABVC
Aug 14, 2025
ABVCGeneral

ABVC BioPharma, Inc. Reports 103% Year-Over-Year

ABVC BioPharma, Inc. has reported a significant 103% increase in year-over-year assets and secured $350,000 in licensing revenue in July 2025. The company's second-quarter results show a reduced diluted loss per share, reflecting its focus on operational efficiency. ABVC's recent acquisition of farmland in Taiwan aims to support its research and manufacturing capabilities in Asia. The CEO highlighted these initiatives as part of the company's strategy for sustainable long-term growth and enhancing shareholder value.

Read more →
ABVC
May 14, 2025
ABVCGeneral
▼ -13.1%on this news· ran to -28% by day 1

ABVC BioPharma Regains Nasdaq Minimum Bid Price

ABVC BioPharma has successfully regained compliance with Nasdaq's minimum bid price, confirming a closing bid price above $1.00 for 10 consecutive trading days. This achievement highlights the company's turnaround strategy and commitment to enhancing shareholder value. Additionally, ABVC is entering discussions with major pharmaceutical and AI firms for the co-development of its Phase III-ready candidates for Major Depressive Disorder and ADHD. The company is focusing on building a platform for future commercialization while maintaining high listing standards.

Read more →
ABVC
May 1, 2025
ABVCGeneral

ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan

ABVC BioPharma announced its financial results for Q1 2025 and outlined plans for a potential AI-enabled agricultural project in Taiwan. The company recognized a land asset valued at $7.67 million for this development, which aims to enhance agricultural practices through precision technology. Despite optimistic projections, the company acknowledges that the project's realization is uncertain. Additionally, financial data reflects a significant operating loss compared to the previous year, highlighting ongoing challenges as the company seeks to enhance its drug pipeline and infrastructure.

Read more →
ABVC
Apr 16, 2025
ABVCGeneral
▲ +8.3%on this news

ABVC BioPharma Announces 2024 Financial Results

ABVC BioPharma announced its financial results for the fiscal year ended December 31, 2024, highlighting a significant revenue growth of 234% to $509,589, primarily driven by licensing payments. Expenses also decreased by 21% to $5.21 million, showcasing improved cost management. Moreover, the company's earnings per share improved by 77%, with a narrower net loss of $4.90 million. ABVC has the potential to receive up to $18.3 million in additional milestone payments under its current licensing agreements, enhancing its growth prospects.

Read more →
ABVC
Jan 13, 2025
ABVCGeneral

ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance with Nasdaq Bid Price Requirement

ABVC BioPharma, Inc. has been granted an additional 180-day grace period by Nasdaq to meet its minimum bid price requirement, extending the deadline to July 7, 2025. The company is committed to regaining compliance by monitoring its stock price and taking necessary steps during this period. ABVC has shown compliance with all other Nasdaq listing requirements and is optimistic about its future growth and development plans.

Read more →
ABVC
Nov 14, 2024
ABVCGeneral

ABVC BioPharma Inc. Reports Q3 2024 Financial Results and Operational Milestones ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year. Incremental Payments Rec

ABVC BioPharma, Inc. reported its Q3 2024 financial results, achieving its first operational profit and a 102% improvement compared to the prior year. The company is advancing in clinical trials for its major depressive disorder and ADHD programs, with important regulatory moves for its vitreous substitute, Vitargus. Recent licensing agreements have positioned ABVC to potentially generate significant revenue streams. Despite a negative EPS due to interest expenses, management expressed confidence in their growth trajectory and future value creation.

Read more →
ABVC
Aug 20, 2024
ABVCGeneral
▲ +6.2%on this news

Corporate Overview NASDAQ: ABVC 2024 2 Forward Looking Statements This presentation contains summary information about ABVC BioPharma, Inc . ("ABVC") as of the date hereof . The information in this presentation is of gen

ABVC BioPharma has released an overview detailing its corporate strategy and financial performance for Q2 2024. The company reported a notable increase in revenue from $6,109 in Q2 2023 to $117,142 in the same quarter of 2024. Additionally, ABVC's earnings per share improved significantly. Its pipeline includes promising candidates for Major Depressive Disorder and ADHD, with recent advancements in patent approvals and licensing agreements suggesting positive future prospects.

Read more →
ABVC
Aug 15, 2024
ABVCGeneral
▼ -5.2%on this newsshared move

ABVC BioPharma Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements Executed Global Licensing Agreements that could provide up to $292 million in income Received Cash Milestone Incomes of $116,000 Ach

ABVC BioPharma Inc. reported strong financial results for Q2 2024, including significant licensing agreements that could provide up to $292 million in income. The company achieved an 86.8% year-over-year improvement in earnings per share and recorded substantial revenue growth. While the financial outlook appears promising, the potential income from licensing agreements remains contingent on product success. Recent patent approvals and advancements in clinical trials further bolster ABVC's strategic position in the biopharmaceutical market.

Read more →
ABVC
May 24, 2024
ABVCGeneral
▼ -9.1%on this news

Immunity Boosting Combination Therapy for Myelodysplastic Syndrome Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont,

ABVC BioPharma has formed a significant collaboration with OncoX BioPharma to develop a combination therapy for Myelodysplastic Syndrome (MDS), announcing the potential for an aggregate income of $13.75M and royalties up to $12.50M. The partnership marks a hopeful advance in MDS treatment, aiming to improve patient outcomes through innovative therapeutic approaches. However, there are uncertainties regarding both the financial outcomes and the success of the therapy, as regulatory approvals and market dynamics remain unpredictable.

Read more →
ABVC
May 16, 2024
ABVCGeneral

Promising Combination Therapy for Tripple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M Fremont, CA (

ABVC BioPharma has announced a partnership with OncoX BioPharma to develop a combination therapy for Triple Negative Breast Cancer (TNBC). The collaboration includes a significant financial agreement potentially worth up to $13.75 million, along with royalties on future sales. This effort aims to improve treatment options for TNBC, a challenging subtype of breast cancer that currently lacks effective therapies. Both companies will contribute their expertise in drug development towards clinical trials and regulatory proceedings. However, the outcome and timeline for the therapy remain uncertain.

Read more →
ABVC
May 9, 2024
ABVCGeneral

Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont, CA (

ABVC BioPharma, in collaboration with OncoX BioPharma, announced a partnership to develop a combination therapy for pancreatic cancer. This collaboration includes a license fee of $12.5 million and milestone payments as part of their agreement, signaling a strong financial expectation from the partnership. The therapy aims to improve patient outcomes by leveraging the strengths of both companies in oncology treatment. However, uncertainties remain about the successful development and commercialization of the product, alongside potential challenges in financing and regulatory approvals.

Read more →
ABVC
Apr 16, 2024
ABVCGeneral

ABVC Biopharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont, CA (

ABVC Biopharma has entered a global licensing agreement with OncoX to develop and distribute a botanical drug extract for treating Non-Small Cell Lung Cancer (NSCLC). The agreement anticipates an aggregate income of $13.75 million and royalties of up to $12.50 million, contingent on future sales. This collaboration is aimed at enhancing treatment options and expediting patient access to innovative therapies. Both companies will combine their strengths to advance the clinical program for the promising therapy BLEX 404.

Read more →
ABVC
Mar 26, 2024
ABVCGeneral
▲ +21.9%on this news

ABVC Biopharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M Fremont, CA (

ABVC Biopharma has entered a global licensing agreement with ForSeeCon Eye Corporation for its ophthalmology product, Vitargus. The deal includes an initial licensing payment of $30 million and royalties of up to $60 million based on future sales. ABVC's CEO highlights the potential to improve patient quality of life during vitrectomy procedures through this collaboration. This agreement positions ABVC to expand its reach in the ophthalmic market, which is projected to grow significantly over the next several years.

Read more →
ABVC
Mar 14, 2024
ABVCGeneral

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update Fremont, CA (

ABVC BioPharma has released its annual financial results for 2023, highlighting a commitment to improve health outcomes through botanically derived solutions. Significant developments include a global licensing agreement for CNS drugs, which positions the company toward profitability with potential royalties. Additionally, the company has regained Nasdaq compliance and expanded its patent portfolio for various health indications. However, concerns remain regarding its reliance on external financing and the impact of convertible notes on shareholder value.

Read more →
ABVC
Feb 8, 2024
ABVCGeneral
▼ -7.1%on this news

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share Fremont, CA

ABVC BioPharma has signed an agreement to acquire real estate in Taoyuan City, Taiwan, valued at approximately $2.96 million. The acquisition, executed through an equity transfer at a price of $3.50 per share, is intended to support the development of plant factories to grow raw materials for ABVC's botanical drug pipeline. This investment is viewed as an opportunity to enhance shareholder equity and foster collaborations in the Asian healthcare market. The transaction involves a related party, which may introduce governance considerations but reflects strategic positioning in a growing sector.

Read more →
ABVC
Nov 15, 2023
ABVCGeneral
▲ +11.6%on this news· ran to +51% by day 3

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results FREMONT, CA

ABVC BioPharma reported its third-quarter financial and operational results, showcasing progress in clinical trials and strategic partnerships. The company announced successful Phase II trial results for its drug ABV-1504 aimed at treating Major Depressive Disorder, with plans for a Phase III meeting with the FDA. It has also formed a licensing agreement with Xinnovation for its ADHD and MDD drugs, which could yield up to $20 million. The establishment of a partnership with Zhonghui for a health initiative in China was also highlighted.

Read more →
ABVC
Aug 17, 2023
ABVCGeneral
▼ -7.2%on this news

ABVC Executes Cooperation Agreement for Strategic Investments Fremont, CA

ABVC BioPharma, Inc. has announced a Cooperation Agreement with Zhonghui United Technology to exchange a 20% ownership stake in a real estate property. Valued at approximately $7.4 million, this agreement will support the establishment of a healthcare center focusing on senior living and various medical care areas. The collaboration aims to contribute to rural revitalization and foster innovation in ABVC's target fields, including Oncology and Ophthalmology. This partnership signifies ABVC's commitment to company growth and global expansion in the biopharmaceutical sector.

Read more →

About ABVC BioPharma, Inc.

Fremont, CA 19 employees abvcpharma.com
Headquarters44370 OLD WARM SPRINGS BLVD., FREMONT, CA, 94538
Founded1990
BIOPHARMAWATCH ELITE
Trade the next ABVC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime